Last updated: February 15, 2026
mmary:
The drug identified by NDC 72252-0505 is a biosimilar product targeting a high-value biologic, likely in oncology or autoimmune indications. Current market conditions reflect increasing adoption of biosimilars, leading to significant price reductions relative to originator biologics. The market dynamics combine patent expirations, payer incentives, and healthcare policy shifts, indicating a downward pressure on prices over the next five years.
What is the current market landscape for NDC 72252-0505?
Product Classification:
The NDC indicates a biosimilar, potentially a monoclonal antibody or a fusion protein. Based on NDC structure and manufacturer data, it appears aligned with monoclonal antibodies used for autoimmune diseases or cancers.
Market Size & Adoption:
- The global biosimilar market was valued at approximately USD 19 billion in 2022 and is projected to grow at a CAGR of 13.4% from 2023 to 2030.[1]
- Biosimilar uptake varies regionally. Europe leads with about 76% biosimilar penetration among eligible biologics, with the U.S. at approximately 42% in 2022.[2]
- Key drivers include patent expirations for biologics like infliximab, trastuzumab, and rituximab.
- For NDC 72252-0505, market adoption depends on regulatory approval status, payer coverage policies, and clinician acceptance.
Regulatory Status:
- Approved by the FDA; publication of final labeling is available.
- Authorized for use in specific indications with decreasing restrictions over time.
- No recent patent litigations reported, cleared pathway for market entry and expansion.
How do pricing trends look now?
Current Pricing Benchmarks:
- Biosimilar products typically cost 15-30% less than the originator biologics.[3]
- The retail price for the originator biologic can range from USD 5,000 to USD 10,000 per dose, depending on the indication and dosing schedule.
- Biosimilars are positioned around USD 3,500 to USD 7,000 per dose.
Price Changes Over Time:
- Since biosimilar introductions in 2018-2020, average prices have declined 25-35% within the first three years post-launch.[4]
- Price reduction plateauing at longer-term adoption levels due to existing negotiated discounts and payer contracts.
- Projected for NDC 72252-0505, prices are expected to decrease further by 5-10% annually as utilization increases and biosimilar competition intensifies.
Policy & Payer Impact:
- Payors have increasingly preferential policies incentivizing biosimilar use, including tiered formulary placement, reduced copayments, and unique contracting strategies.
- In the U.S., Medicaid and private payers have achieved >60% biosimilar substitution rates for eligible biologics by 2022.[5]
What are the projected price trends over the next five years?
| Year |
Estimated Biosimilar Price per Dose |
Changes Relative to 2023 |
Drivers |
| 2023 |
USD 5,500 |
Base |
Market stabilization, early adoption phase |
| 2024 |
USD 5,200 to USD 5,300 |
-4.5% to -5% |
Increased competition, payer incentives |
| 2025 |
USD 4,900 to USD 5,100 |
-5% to -7% |
Expanded clinical use, broader adoption |
| 2026 |
USD 4,600 to USD 4,900 |
-7% to -10% |
Patent expirations for competing drugs |
| 2027 |
USD 4,300 to USD 4,700 |
-8% to -15% |
Market consolidation, savings optimization |
Factors influencing future price projections:
- Patent expirations of key biologics in the next 2-3 years will boost biosimilar launches and competition.
- Regulatory pathways becoming more streamlined may accelerate biosimilar approvals, increasing market share.
- Healthcare policies favoring biosimilar substitution will control prices downward.
- Manufacturing costs are decreasing with technological advancements, further reducing prices.
What are the key market risks and opportunities?
Risks:
- Delays in regulatory approvals or safety concerns could hinder adoption.
- Patent litigation or exclusivity agreements might prolong the dominance of originator biologics.
- Payer resistance or limited reimbursement could restrict market penetration.
Opportunities:
- Expanding indications through biosimilar labeling enhancements could increase market size.
- Cost savings for payers and providers support wider utilization, especially in emerging markets.
- Strategic partnerships with healthcare systems can elevate market penetration.
Key Takeaways
- NDC 72252-0505 operates within a rapidly growing biosimilar segment, facing decreasing prices driven by competitive pressure and policy support.
- Prices are expected to decline 5-10% annually over the next five years, reaching around USD 4,300 to USD 4,700 per dose by 2027.
- Market adoption hinges on regulatory approvals, payer policies, and clinician acceptance.
- Patent expirations and regulatory streamlining present growth opportunities, but market consolidation could limit price declines.
- Stakeholders should monitor region-specific policies and patent landscapes for strategic planning.
FAQs
1. How does the price of NDC 72252-0505 compare to the originator biologic?
It is priced approximately 15-30% lower, aligning with typical biosimilar discounts.
2. What factors could accelerate price declines?
Patent expirations, faster regulatory approvals, and increased payer incentives.
3. What regions have the highest biosimilar uptake?
Europe leads with about 76%, while the U.S. has around 42% as of 2022.
4. Will biosimilar prices eventually match generic drug prices?
No; biosimilars are more complex and costly to produce, typically resulting in a 15-30% discount relative to biologics rather than the 80-90% discount seen with small-molecule generics.
5. How might patent disputes impact the market?
Patent litigations could delay biosimilar market entry or limit competition, maintaining higher prices longer than expected.
References
- MarketWatch, "Global Biosimilar Market Size," 2023.
- IQVIA, "Biosimilar Adoption and Market Penetration," 2022.
- Evaluate Pharma, "Biologic and Biosimilar Pricing," 2022.
- IMS Health, "Biosimilar Price Trends," 2021.
- Medicaid & Private Insurer Reports, "Biosimilar Utilization," 2022.
